Strontium-89 Chloride in Combined Treatment of Hormone Resistant Prostatic Cancer
https://doi.org/10.17650/1726-9776-2006-2-1-38-40
Abstract
Hormone resistant phase of prostatic cancer develops after 16-24 months of hormone therapy of metastatic prostatic cancer. Radiopharmaceutical method of treatment is essential for pain control in multiple metastases in the bones; we mean the use of beta-emission isotope strontium-89 chloride (metastrone). Total systems radiotherapy by strontium-89 chloride was carried out as stage III of multiple modality treatment in 90 patients with metastatic hormone-resistant prostatic cancer (HRPC) within the framework of randomized study. Before radiopharmaceutical therapy 18% patients complained of pronounced pain syndrome, 50% presented with moderate pain syndrome, and pathological fractures were diagnosed in 12% patients. Therapy with strontium-89 chloride led to stabilization of the pain syndrome during therapy in 72.7% and to its progress in 27.3% patients. This therapy was well tolerated in general. It can be used as a stage in combined treatment of HRPC patients.
About the Authors
A. D. Kaprin
Russian National Center of Roentgenology and Radiology
Russian Federation
Moscow
Russian Federation
Moscow
Yu. N. Smirnov
Russian National Center of Roentgenology and Radiology
Russian Federation
Moscow
Russian Federation
Moscow
R. A. Gafanov
Russian National Center of Roentgenology and Radiology
Russian Federation
Moscow
Russian Federation
Moscow
A. A. Kostin
Russian National Center of Roentgenology and Radiology
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2001 г. – М., 2003. – С. 7–10; 100–102.
2. Partin A.W., Yoo J., Carter H.B. et al. The use of prostate specific antigen clinical stage Gleason and reason score to predict pathological stage in men with localized prostate cancer // J. Urol. – 1993; 150:110.
3. Scher H., Steinneck G., Kelly W.K. Hormone-refractory (D3) prostate cancer: refining the concept // Urology. – 1995; 46:142–148.
4. Vogelzang N.J., Crawford E.D., Zietman A. Current clinical trial design issues in hormone-refractory prostate cancer // Cancer. – 1998; 82:2093–2101.
5. Babley G.J., Carducci M., Dahur W. et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group // J. Clin. Oncol. – 1999; 17:3461–3467.
6. Goodin S., Rao K.V., DiPaola R.S. State-of-the-art treatment of metastatic hormone-refractory prostate cancer // Oncologist. – 2002; 7(4):360–370.
7. Rosental M.A. Advanced in the management of prostate cancer // Austral. N. Z. J. Med. – 2000; 30(5):593–599.
8. Isaacs J.T. The biology of hormone-factory prostate cancer. Why does it develop? // Urol. Clin. North. Am. – 1999; 26:263–273.
9. Oh W.K., Kanthoff P.W. Management of hormone refractory prostate cancer: current standarts and future prostests // J. Urol. – 1998; 160:1220–1229.
10. Kirby R.S., Christmas T.J., Brawer M.K. et al. Prostate cancer // Second. edition. – 2001; 187–198.
Review
For citations:
Kaprin A.D., Smirnov Yu.N., Gafanov R.A., Kostin A.A. Strontium-89 Chloride in Combined Treatment of Hormone Resistant Prostatic Cancer. Cancer Urology. 2006;2(1):38-40. (In Russ.) https://doi.org/10.17650/1726-9776-2006-2-1-38-40
Views:
456
Email this article 